Epizyme (EPZM) Plans Presentation of Tazemetostat Phase 1/2 Data at ECC 2015
Tweet Send to a Friend
Epizyme (NASDAQ: EPZM) announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
